Systemic Treatment

EpisodeEvent element containing the data regarding the patient's cancer

Select the type of Systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy; Immunotherapy; Target therapy; Unknown

Chemotherapy - 4273629 Immunotherapy - 40310107 Target therapy - 40488979 Unknown - 4129922

Clarifies the reasons why Other therapy is administered ? Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. ? Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as ??treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor?related symptoms??

Palliative; Curative; Unknwon Palliative - 4179711 Curative - Unknown - 4129922

clarifies the context / how the therapy was administered alone or in conjunction with other treatments ? Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. ? Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. ? Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy + radiotherapy).

Neo-adjuvant; Concomitant; Adjuvant; Other tretament alone; Unknown; Neo-adjuvant - 44808409 Concomitant - Adjuvant - 44804498 Other tretament alone - Unknown - 4129922

Information for computed tomography

Pre-operative; Post-operative; Intra-operative (hypertermic intraperiotoneal chemotherapy HIPEC ); therapeutic (without surgery) Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when Other treatment begins

Specifies when Other treatment ends

clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

Regimen

Drugs 1

ATC list Athena vocabulary ATC

Drugs 2

ATC list Athena vocabulary ATC

Drugs 3

ATC list Athena vocabulary ATC

specifies when the new Other treatment begins, if a combination please specify the start of the first drug

specifies when the new Other treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completion; Toxicity; Comorbidity; Patient intolerance; Patients decision; Death; Unknown. Completion - 4058777 Toxicity - 438028 Comorbidity - 4162706 Patient intolerance - 4105297 Patients decision - Death - 4306655 Unknown - 4129922

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete response; Partial response; Stable disease; Progression; Unknown. Complete response - 4163135 Partial response - 4161302 Stable disease - 4241442 Progression - 4168352 Unknown - 4129922

Systemic Treatment

EpisodeEvent element containing the data regarding the patient's cancer

Select the type of Systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy; Immunotherapy; Target therapy; Unknown

Chemotherapy - 4273629 Immunotherapy - 40310107 Target therapy - 40488979 Unknown - 4129922

Clarifies the reasons why Other therapy is administered ? Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. ? Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as ??treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor?related symptoms??

Palliative; Curative; Unknwon Palliative - 4179711 Curative - Unknown - 4129922

clarifies the context / how the therapy was administered alone or in conjunction with other treatments ? Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. ? Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. ? Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy + radiotherapy).

Neo-adjuvant; Concomitant; Adjuvant; Other tretament alone; Unknown; Neo-adjuvant - 44808409 Concomitant - Adjuvant - 44804498 Other tretament alone - Unknown - 4129922

Information for computed tomography

Pre-operative; Post-operative; Intra-operative (hypertermic intraperiotoneal chemotherapy HIPEC ); therapeutic (without surgery) Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when Other treatment begins

Specifies when Other treatment ends

clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

Regimen

May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

Modifier extensions allow for extensions that cannot be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the definition of modifier extensions.

Drugs 1

ATC list Athena vocabulary ATC

Drugs 2

ATC list Athena vocabulary ATC

Drugs 3

ATC list Athena vocabulary ATC

specifies when the new Other treatment begins, if a combination please specify the start of the first drug

specifies when the new Other treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completion; Toxicity; Comorbidity; Patient intolerance; Patients decision; Death; Unknown. Completion - 4058777 Toxicity - 438028 Comorbidity - 4162706 Patient intolerance - 4105297 Patients decision - Death - 4306655 Unknown - 4129922

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete response; Partial response; Stable disease; Progression; Unknown. Complete response - 4163135 Partial response - 4161302 Stable disease - 4241442 Progression - 4168352 Unknown - 4129922

Systemic Treatment

EpisodeEvent element containing the data regarding the patient's cancer

Select the type of Systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy; Immunotherapy; Target therapy; Unknown

Chemotherapy - 4273629 Immunotherapy - 40310107 Target therapy - 40488979 Unknown - 4129922

Clarifies the reasons why Other therapy is administered ? Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. ? Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as ??treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor?related symptoms??

Palliative; Curative; Unknwon Palliative - 4179711 Curative - Unknown - 4129922

clarifies the context / how the therapy was administered alone or in conjunction with other treatments ? Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. ? Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. ? Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy + radiotherapy).

Neo-adjuvant; Concomitant; Adjuvant; Other tretament alone; Unknown; Neo-adjuvant - 44808409 Concomitant - Adjuvant - 44804498 Other tretament alone - Unknown - 4129922

Information for computed tomography

Pre-operative; Post-operative; Intra-operative (hypertermic intraperiotoneal chemotherapy HIPEC ); therapeutic (without surgery) Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when Other treatment begins

Specifies when Other treatment ends

clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

Regimen

Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.

May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

Modifier extensions allow for extensions that cannot be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the definition of modifier extensions.

Drugs 1

ATC list Athena vocabulary ATC

Drugs 2

ATC list Athena vocabulary ATC

Drugs 3

ATC list Athena vocabulary ATC

specifies when the new Other treatment begins, if a combination please specify the start of the first drug

specifies when the new Other treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completion; Toxicity; Comorbidity; Patient intolerance; Patients decision; Death; Unknown. Completion - 4058777 Toxicity - 438028 Comorbidity - 4162706 Patient intolerance - 4105297 Patients decision - Death - 4306655 Unknown - 4129922

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete response; Partial response; Stable disease; Progression; Unknown. Complete response - 4163135 Partial response - 4161302 Stable disease - 4241442 Progression - 4168352 Unknown - 4129922